FORWARD-LOOKING STATEMENTS

Except for the historical information set forth herein, the matters set forth in this presentation contain predictions, estimates and other forward-looking statements, including without limitation statements regarding: the expected timing of submission of an NDA for parsaclisib; the transformational growth potential of our portfolio, including expectations regarding continued growth from Jakafi, the opportunity for once-a-day ruxolitinib, the potential for targeted combinations and new molecules for MPNs and GVHD; expectations regarding the commercialization of Monjuvi and Pemazyre, the potential development of additional hematology and oncology compounds, including parsaclisib, expectations for ruxolitinib cream and INCB54707, and potential growth in royalties from new indications and new geographies; expectations to diversify our revenue streams; expectations regarding the timing of FDA decisions for ruxolitinib for cGVHD and ruxolitinib cream in atopic dermatitis; our 2020 guidance for Jakafi and future revenue outlook for our products for MPNs and GVHD; expectations regarding the receipt or presentation of clinical trial results for various of our and our collaborative partners’ product candidates; expectations regarding the initiation or completion of clinical trials for various of our product candidates; expectations with respect to the potential for Monjuvi and the benefit it brings to eligible patients; our commercial plans for our dermatology program; expectations regarding the timing of submission of an sNDA for ruxolitinib cream in vitiligo; and our expectations regarding 2021 newsflow items.

These forward-looking statements are based on our current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays, including unanticipated delays in the submission of the Company's NDA for parsaclisib; the actual time required by the FDA to review the Company’s sNDA for ruxolitinib for cGVHD and NDA for ruxolitinib cream in atopic dermatitis, and the results of such reviews; the effects of the COVID-19 pandemic and measures to address the pandemic on our clinical trials, supply chain and third-party providers, sales and marketing efforts, and business, development and discovery operations as well as on regulatory agencies such as the FDA; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; determinations made by the FDA and regulatory agencies outside of the United States; our dependence on relationships with and changes in the plans and expenditures of our collaboration partners; the efficacy or safety of our products and the products of our collaboration partners; the acceptance of our products and the products of our collaboration partners in the marketplace; market competition; unexpected variations in the demand for our products and the products of our collaboration partners; the effects of announced or unexpected price regulation or limitations on reimbursement or coverage for our products and the products of our collaboration partners; sales, marketing, manufacturing and distribution requirements, including our and our collaboration partners’ ability to successfully commercialize and build commercial infrastructure for newly approved products and any additional new products that become approved; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our quarterly report on Form 10-Q for the quarter ended September 30, 2020. We disclaim any intent or obligation to update these forward-looking statements.
Growth rates represent 9 month on 9 month growth. Jakavi (ruxolitinib) licensed to Novartis ex-US, Tabrecta (capmatinib) licensed to Novartis worldwide; Olumiant (baricitinib) licensed to Lilly worldwide; these brands are trademarks of Novartis (Jakavi and Tabrecta) and Lilly (Olumiant). Iclusig (ponatinib) is a registered trademark of ARIAD. Monjuvi (tafasitamab-cixv) is a registered trademark of MorphoSys.

*Does not include Monjuvi revenues of $5m in Q3 2020 (recognized by MorphoSys).
SIGNIFICANT CLINICAL PROGRESS IN 2020

MPNs and GVHD

- **Jakafi®**: REACH3 results in SR chronic GVHD; sNDA submitted
- **LIMBER**: once-a-day ruxolitinib development progressing
- **LIMBER**: ruxolitinib+parsaclisib PoC data in MF
- **LIMBER**: ruxolitinib+parsaclisib Phase 3 program underway
- **LIMBER**: PoC trials underway for INCB57643 (BET) and INCB00928 (ALK2)

Hematology/Oncology

- **Monjuvi®**: FDA approval in r/r DLBCL
- **Pemazyre®**: FDA approval in cholangiocarcinoma
- **retifanlimab**: POD1UM-202 results in advanced SCAC
- **parsaclisib**: CITADEL results in NHL

Dermatology

- **ruxolitinib cream**: NDA submitted in atopic dermatitis
- **ruxolitinib cream**: Phase 3 program in vitiligo fully recruited
- **INCB54707**: Preliminary efficacy and safety data in hidradenitis suppurativa

Royalties

- **Tabrecta®**: FDA and Japanese approval in METex14 NSCLC
- **Olumiant®**: EU and Japanese approval in AD; Phase 2 data in alopecia areata

Tabrecta (capmatinib) licensed to Novartis worldwide, Olumiant (baricitinib) licensed to Lilly worldwide; these brands are trademarks of Novartis (Tabrecta) and Lilly (Olumiant).

Monjuvi (tafasitamab-cxix) is a registered trademark of MorphoSys. Retifanlimab licensed from MacroGenics. GVHD = graft versus host disease; MF = myelofibrosis; DLBCL = diffuse large B-cell lymphoma; SCAC = squamous cell carcinoma of the anal canal; NHL = non-Hodgkin lymphoma; NSCLC = non small-cell lung cancer; AD = atopic dermatitis.
TRANSFORMATIONAL GROWTH POTENTIAL

- Continued growth from Jakafi®
- Opportunity for once-a-day ruxolitinib
- Targeted combinations to improve outcomes
- New molecules against novel targets
- Monjuvi® & Pemazyre® launches
- Development of parsaclisib, retifanlimab & INCB86550
- Emerging clinical programs: A₂A/A₂B, AXL/MER & PD-L1xCD137
- Ruxolitinib cream in atopic dermatitis & vitiligo
- INCB54707: a selective JAK1 for hidradenitis suppurativa
- Dedicated commercial & development teams
- Growth from new indications and new geographies
Jakavi (ruxolitinib) licensed to Novartis ex-US, Tabrecta (capmatinib) licensed to Novartis worldwide, Olumiant (baricitinib) licensed to Lilly worldwide; these brands are trademarks of Novartis (Jakavi and Tabrecta) and Lilly (Olumiant). Iclusig (ponatinib) is a registered trademark of ARIAD. Monjuvi (tafamidis-mex) is a registered trademark of MorphoSys. Retifanlimab licensed from MacroGenics.

- Jakafi®
- QD ruxolitinib
- QD rux+PI3Kδ
- QD rux+BET
- QD rux+ALK2
- itacitinib
- Novel targets

- Monjuvi®
- Pemazyre®
- Iclusig®
- parsaclisib
- retifanlimab
- INCB86550
- New clinical candidates

- ruxolitinib cream
- INCB54707

- Jakavi®
- Tabrecta®
- Olumiant®

Incyte
Growth and diversification

MPNs and GVHD

Dermatology

Hematology/Oncology

Royalties

SOLVE ON.
Jakavi® licensed to Novartis ex-US, Tabrecta (capmatinib) licensed to Novartis worldwide, Olumiant (baricitinib) licensed to Lilly worldwide; these brands are trademarks of Novartis (Jakavi and Tabrecta) and Lilly (Olumiant). Iclusig (ponatinib) is a registered trademark of ARIAD. Monjuvi (tafasitamab-cixix) is a registered trademark of MorphoSys. Retifanlimab licensed from MacroGenics.
SUCCESSFUL RANDOMIZED PHASE 3 IN CHRONIC GHVD
RUXOLITINIB SUPERIOR TO BEST AVAILABLE THERAPY IN STEROID-REFRACTORY PATIENTS

REACH3 efficacy summary (RUX vs BAT)

- Significantly higher ORR¹ (49.7% vs 25.6%)
- Higher best overall response rate (76.4% vs 60.4%)
- Greater mLSS responder rate¹ (24.2% vs 11.0%)
- Longer duration of response (NR vs 6m)
- Significant improvement in failure-free survival (NR vs 6m)

Safety consistent with previous observations

- As expected in patients with chronic GVHD

Next Steps:

- sNDA submitted; FDA decision expected in H2 2021

**cGVHD** = chronic graft-versus-host disease. NR = not reached; ORR = overall response rate; FFS = failure-free survival.

1. At week 24
2. Descriptive P value at the primary analysis (non-US testing sequence only) as the efficacy boundary was crossed at the interim analysis (N=196; HR, 0.315 [95% CI, 0.205-0.486]; P<0.0001). For US testing sequence, the hypothesis was retested at the primary analysis following the overall hierarchical testing procedure.
EXPANSION BEYOND JAKAFI®
DEVELOPING NEW THERAPEUTIC OPTIONS IN MPNs AND GVHD

- QD ruxolitinib
- QD rux+PI3Kδ
- QD rux+BET
- QD rux+ALK2
- itacitinib
- Novel molecules

MPNs & GVHD 2027 U.S. revenue outlook
-- >$3 billion

2020 U.S. guidance
-- $1.91-1.94 billion

Jakafi (ruxolitinib) is approved by the FDA for treatment of adults with intermediate or high-risk myelofibrosis, for treatment of adults with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea and for the treatment of steroid-refractory acute GVHD in adult and pediatric patients 12 years and older.
## DEVELOPING NEW OPTIONS FOR MYELOFIBROSIS

### MULTIPLE OPPORTUNITIES TO IMPROVE OUTCOMES FOR PATIENTS

<table>
<thead>
<tr>
<th>Percentage</th>
<th>Description</th>
<th>Opportunities to improve first-line therapy beyond monotherapy JAK inhibition</th>
</tr>
</thead>
<tbody>
<tr>
<td>25%</td>
<td>Recently diagnosed; not yet on therapy</td>
<td>- ~50% of patients have a suboptimal response to single agent JAK inhibition¹</td>
</tr>
<tr>
<td>55%</td>
<td>Currently treated with Jakafi®</td>
<td>- ~50% of patients are on sub-therapeutic dose because of anemia and could benefit from increased JAK dose intensity²</td>
</tr>
<tr>
<td>20%</td>
<td>Previously treated with Jakafi®</td>
<td>- ~30% of patients discontinue after 6 months; top three reasons are thrombocytopenia, anemia and disease progression²</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>QD ruxolitinib</th>
<th>QD ruxolitinib + PI3Kδ</th>
<th>QD ruxolitinib + BET</th>
<th>QD ruxolitinib + ALK2</th>
<th>itacitinib</th>
<th>Novel molecules</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potential for FDCs with QD ruxolitinib</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

1. Verstovsek et al, NEJM 2012
2. U.S. market audit Q2 2020

---

**Incyte**

~16,000 Jakafi eligible MF patients in the U.S.
NEW OPTION IN LIMBER PORTFOLIO FROM CELLENKOS®
RUXOLITINIB PLUS ALLOGENEIC CORD BLOOD-DERIVED T-REGULATORY CELLS

CK0804 is a novel allogeneic cell therapy product
✓ Cord blood-derived T-regulatory cells (CB-Tregs)
✓ Enriched to exploit the CXCR4/CXCL12 axis
  ➢ Enabling targeting of bone marrow in MF patients
✓ Cryopreserved and available off-the-shelf
✓ No requirement for HLA matching

Financial terms
▪ Incyte to fund PoC trial
▪ Option to license program for $20m upfront
▪ Success-based milestones and tiered royalties on sales

Early clinical data
➢ Patient with heavily pre-treated primary myelofibrosis
➢ Taking Jakafi® as fourth-line therapy for ~5 years, added CB-Tregs

Kadia et al., Blood (2020) 136 (Supplement 1): 41–42
MULTIPLE PIVOTAL TRIALS PLANNED AND UNDERWAY

- **MF**
  - QD ruxolitinib ➞ FDA decision
  - rux+PI3Kδ ➞ P3 results ➞ FDA decision
  - rux+BET ➞ PoC trials ➞ P3 results
  - rux+ALK2 ➞ PoC trials ➞ P3 results
  - itacitinib ➞ PoC trials ➞ P3 results
  - rux+CK0804² ➞ PoC trials

- **PV**
  - QD ruxolitinib ➞ FDA decision
  - New molecules ➞ PoC trials

- **GVHD**
  - QD ruxolitinib ➞ FDA decision
  - itacitinib ➞ P3 results

**U.S. patent exclusivity¹**
- QD ruxolitinib (JAK1/2, 2033)
- parsaclisib (PI3Kδ, 2032)
- INCB57643 (BET, 2035)
- INCB00928 (ALK2, 2037)
- itacitinib (JAK1, 2031)

---

1. Status of current United States patent estate (earliest anticipated expirations, subject to potential extensions)
2. Development of CK0804 plus ruxolitinib in collaboration with Cellenkos
Jakavi® (ruxolitinib) licensed to Novartis ex-US, Tabrecta (capmatinib) licensed to Novartis worldwide, Olumiant (baricitinib) licensed to Lilly worldwide; these brands are trademarks of Novartis (Jakavi and Tabrecta) and Lilly (Olumiant). Iclusig (ponatinib) is a registered trademark of ARIAD. Monjuvi (tafasitamab-cixix) is a registered trademark of MorphoSys. Retifanlimab licensed from MacroGenics.
Development and U.S. commercialization of tafasitamab in collaboration with MorphoSys. Monjuvi (tafasitamab-cxix) is a CD19-directed cytolytic antibody indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). CR = complete response; PR = partial response; DOR = duration of response; NR = not reached; OS = overall survival.

1. DLBCL ATU Wave 1, September 2020. 2. DLBCL Tafasitamab Segmentation and Demand Study, April 2020
# TAFASITAMAB: GLOBAL CLINICAL DEVELOPMENT

<table>
<thead>
<tr>
<th>Study</th>
<th>Arms</th>
<th>Status</th>
<th>PoC</th>
<th>Pivotal</th>
</tr>
</thead>
<tbody>
<tr>
<td>L-MIND (~80 pts)</td>
<td>+ lenalidomide</td>
<td>FDA approved in 2L+ DLBCL</td>
<td>Primary endpoint: ORR (2-year analysis presented at EHA 2020)</td>
<td></td>
</tr>
<tr>
<td>B-MIND (~450 pts)</td>
<td>+ bendamustine vs bendamustine + rituximab</td>
<td>Ongoing, data expected 2022</td>
<td>Primary endpoint: PFS (IDMC futility passed November 2019)</td>
<td></td>
</tr>
<tr>
<td>inMIND; FL &amp; MZL (~600 pts)</td>
<td>+ R² (lenalidomide + rituximab) vs R²</td>
<td>Trial expected to start in 2021</td>
<td>Primary endpoint: PFS</td>
<td></td>
</tr>
<tr>
<td>B-cell malignancies</td>
<td>+ parsaclisib</td>
<td>Trial expected to start in 2021</td>
<td>Trial expected to start in 2021</td>
<td></td>
</tr>
<tr>
<td>B-cell malignancies</td>
<td>+ lenalidomide + plamotamab¹</td>
<td>Trial expected to start in 2021</td>
<td>Trial expected to start in 2021</td>
<td></td>
</tr>
</tbody>
</table>

Development and U.S. commercialization of tafasitamab in collaboration with MorphoSys. Monjuvi (tafasitamab-cxix) is a CD19-directed cytolytic antibody indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). PFS = progression-free survival.

1. In collaboration with and sponsored by Xencor.
DELIVERING ON THE PROMISE OF PI3Kδ INHIBITION

PARSACLISIB NDA EXPECTED IN H2 2021

Development strategy to optimize patient benefit

- Highly selective and potent next-gen PI3Kδi
- Designed to avoid hepatotoxicity associated with first-gen PI3Kδ inhibitors
- Dosing regimen to mitigate cumulative on-target toxicities
  - 20mg once daily for 8 weeks
  - 2.5mg once daily thereafter

Efficacy across non-Hodgkin lymphomas

<table>
<thead>
<tr>
<th></th>
<th>ORR</th>
<th>DOR</th>
<th>PFS</th>
</tr>
</thead>
<tbody>
<tr>
<td>r/r FL</td>
<td>75%</td>
<td>14.7m</td>
<td>15.8m</td>
</tr>
<tr>
<td>r/r MZL1</td>
<td>57%</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>r/r MCL1</td>
<td>71%</td>
<td>9.0m</td>
<td>11.1m</td>
</tr>
</tbody>
</table>

Favorable therapeutic ratio among PI3Kδi class2

- Low rates of liver tox: <5% Gr.3+ AST/ALT elevations
- Cases of serious diarrhea (~10%) and colitis (<10%) were manageable and reversible

Significant opportunities in r/r NHL

- Follicular: ~9,000 new patients per year
- Marginal zone: ~5,000 new patients per year
- Mantle cell: ~5,000 new patients per year


ORR = overall response rate; DOR = median duration of response; PFS = median progression-free survival; TEAEs = treatment emergent adverse events

1. BTK-naïve cohort only. 2. Summary safety data from CITADEL-203, CITADEL-204 and CITADEL-205 trials as presented at ASH 2020.
INCB86550: FIRST IN SERIES OF SELECTIVE ORAL ANTI-PD-L1 MOLECULES

Functional PD-L1 inhibition

Clinical activity

Next Steps:
- Assess safety profile
- Evaluate efficacy in defined patient groups
- Additional clinical data presentation expected in H2 2021

"The peripheral immune alterations observed with the administration of the oral PD-L1 inhibitor INCB86550 are consistent with those observed for PD-1 & PD-L1 monoclonal antibodies"
EMERGING CLINICAL CANDIDATES

MULTIPLE THERAPEUTIC TARGETS PROVIDE ADDITIONAL LONG-TERM OPTIONALITY

**PD-L1 x CD137**
- IgG1 bispecific antibody within Merus collaboration
- PD-L1 targeting designed to avoid safety liabilities of other CD137 directed agents
- Inhibits PD-1 axis while simultaneously activating CD137 signaling on T cells

**AXL / MER**
- Selective targeting of TAM receptors, AXL and MER
- Dual AXL/MER inhibition expected to impair oncogenic effects of TAM kinases
- Potential for synergistic activity with PD-1 axis blockade

**A2A / A2B**
- Adenosine is a potent immunosuppressive metabolite in the TME
- Strategy to inhibit multiple nodes within adenosine pathway
- Triple inhibition (w/ PD-1 and CD73) offers maximal potential benefit

MCLA-145 in dose escalation
Clinical data expected 2021

INCB81776 in dose escalation
Clinical data expected 2021

INCB106385 in dose escalation
IND for anti-CD73 MAb expected 2021

---

1. MCLA-145 development in collaboration with Merus; data panel adapted from Mayes et al, AACR 2019
2. Data panel from Favata et al, AACR 2018 [TGI = tumor growth inhibition]
3. Data panel previously unpublished data on file, Incyte
Jakavi (ruxolitinib) licensed to Novartis ex-US, Tabrecta (capmatinib) licensed to Novartis worldwide, Olumiant (baricitinib) licensed to Lilly worldwide; these brands are trademarks of Novartis (Jakavi and Tabrecta) and Lilly (Olumiant). Iclusig (ponatinib) is a registered trademark of ARIAD. Monjuvi (tafasitanab-cxix) is a registered trademark of MorphoSys. Retifanlimab licensed from MacroGenics.
A UNIQUE PROFILE TO MEET PATIENT NEEDS

RUXOLITINIB CREAM EFFICACY ACROSS MULTIPLE IMPORTANT ENDPOINTS

<table>
<thead>
<tr>
<th>Patient Type</th>
<th>ruxolitinib cream¹ mild/moderate</th>
<th>dupilumab² moderate/severe</th>
<th>crisaborole³ mild/moderate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline:</td>
<td>IGA score (proportion)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mean BSA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mean Itch NRS score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IGA-TS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin clearance</td>
<td>41%</td>
<td>27 – 28%</td>
<td>2 &amp; 3 (38.5%/61.5%)</td>
</tr>
<tr>
<td>EASI-75</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin improvement</td>
<td>42%</td>
<td>32 – 36%</td>
<td>NA</td>
</tr>
<tr>
<td>Itch NRS4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reduction of itch</td>
<td>36%</td>
<td>26 – 29%</td>
<td>NA</td>
</tr>
<tr>
<td>PROMIS 8b</td>
<td></td>
<td></td>
<td>7 – 13%</td>
</tr>
<tr>
<td>Improvement in sleep</td>
<td>10%</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

Week 8, vehicle-adj

Week 16, PBO-adj

Day 29, vehicle-adj

Baseline: IGA score (proportion) Mean BSA Mean Itch NRS score

IGA-TS: Investigator’s Global Assessment (IGA)-Treatment Success defined as an IGA score of 0 (clear) or 1 (almost clear) with ≥2-point improvement from baseline at Week 8; EASI-75: ≥75% improvement from baseline at Week 8 in the Eczema Area and Severity Index (EASI) score; NRS: numerical rating scale; PROMIS: Patient-Reported Outcomes Measurement Information System

1. Pooled data from TRuE-AD1 and TRuE-AD2 for 1.5% BID strength. 2. SOLO-1 and SOLO-2 data from Dupixent (dupilumab) prescribing information. 3. Study AD-301 and AD-302 data from Eucrisa (crisaborole) prescribing information.
SIGNIFICANT POTENTIAL FOR RUXOLITINIB CREAM

POTENTIALLY TRANSFORMATIVE THERAPY FOR UNCONTROLLED ATOPIC DERMATITIS

Profile of rux cream is clear differentiator for HCPs¹

- Over 80% of dermatologists surveyed are likely to prescribe ruxolitinib cream
- Majority of dermatologists surveyed would use ruxolitinib cream in 2L after TCS

Unmet medical needs remain in atopic dermatitis²

- Over 90% of patients surveyed were using a topical treatment
- Over 3/4 of patients feel their AD is uncontrolled
- Nearly 2/3 of patients experience itching most days of the week

US Epidemiology of AD

21.2m Prevalence
(7.5% of US Population ≥12 years)

9.6m Diagnosed
(45% of Prevalent)

5.5m Drug Treated

1.6m undiagnosed

2. Survey findings of 657 respondents; fielded December 4, 2019 to April 21, 2020. Sponsored by Health Union.

LAUNCH READINESS IN THE UNITED STATES
FIELD TEAM RECRUITMENT IN PROGRESS, REIMBURSEMENT EXPERTISE IN PLACE

High-impact dermatology team being assembled
- ~150 FTEs anticipated in field force (sales & medical)\(^1\)
- Full recruitment expected by mid-April
- Targeting approximately 11,000 medical specialists\(^2\)

Experienced dermatology specialists already recruited
- Payor access
- Medical affairs
- Marketing

Building momentum throughout 2021
- Strong presence planned at key dermatology congresses
- Academic, community and Ad Board engagements

Next Steps:
- FDA decision in atopic dermatitis expected H1 2021

---

1. FTE = full-time equivalents
2. Target customers expected to include both medical dermatologists and high priority allergists
VITILIGO OFFERS SECOND SUBSTANTIAL OPPORTUNITY

NO FDA-APPROVED THERAPY FOR REPIGMENTATION; >1.5 MILLION U.S. PATIENTS

- Substantial repigmentation of vitiligo lesions
- Continued improvements over time
- Well tolerated therapy

Randomized Phase 2 results

- Vehicle (n=32)
- 0.15% QD (n=31)
- 0.5% QD (n=31)
- 1.5% QD (n=30)
- 1.5% BID (n=33)

Error bars indicate standard error; Harris et al, EADV 2019

Representative patient series treated with ruxolitinib cream 1.5% BID
62 year old male, vitiligo for 20 years, Fitzpatrick skin type III

Next Steps:
- Phase 3 results expected in H1 2021
- sNDA submission expected in H2 2021

F-VASI = facial vitiligo area severity index.
Images used with permission; Harris et al, EADV 2019
INCB54707: ORAL SELECTIVE JAK1 INHIBITOR

POC SHOWN IN HIDRADENITIS SUPPURATIVA; PHASE 2B ONGOING

**Preliminary efficacy demonstrated**

- AN count reduced as early as Week 1 and were maintained
- Improvement Quality of Life demonstrated
- Well tolerated; no treatment discontinuations due to TEAEs

**Phase 2b trial recruiting**

- Randomized, placebo-controlled trial
- n ~200 patients with HS duration ≥ 3 months
- Primary endpoint: Median change in AN count (wk 16)

- **AN Count**
  - Benefit seen as early as week 1

- **Limited treatment options**
  - Standard-of-care: surgical intervention
  - Only approved therapy: Humira for Hurley Stage 2 and 3
  - ~50,000 patients currently being treated in the U.S.

---

1. AN = abscess and inflammatory nodule; HS = hidradenitis suppurativa; EoT = end of treatment; Alavi, et al. SHSA 2020.
IMPORTANT UPDATES EXPECTED IN 2021

**H1 2021**
- **MPNs and GVHD**
  - LIMBER: QD ruxolitinib BA/BE data

- **Hematology/Oncology**
  - Tafasitamab: frontMIND to begin (P3, 1L DLBCL)
  - Tafasitamab: inMIND to begin (P3, r/r FL & MZL)
  - Pemigatinib: MAA & PMDA decisions (r/r CCA\(^1\))

- **Dermatology**
  - Ruxolitinib cream: TRuE-V data (P3, vitiligo)
  - Ruxolitinib cream: FDA decision (atopic dermatitis)

- **Royalties**
  - Olumiant®: FDA decision (atopic dermatitis)
  - Olumiant®: BRAVE-AA data (P3, alopecia areata)

**H2 2021**
- **Jakafi®**: FDA decision (SR chronic GVHD)
- **LIMBER**: JAK+BET PoC trial to begin
- **LIMBER**: JAK+ALK2 PoC trial to begin

- **Hematology/Oncology**
  - Tafasitamab: MAA decision (r/r DLBCL)
  - Parsaclisib: NDA submission (r/r NHL)
  - INCB86550: clinical efficacy & safety data

- **Dermatology**
  - Ruxolitinib cream: sNDA submission (vitiligo)
  - Ruxolitinib cream: MAA submission (vitiligo)

- **Royalties**
  - Olumiant®: BRAVE data (P3, lupus)

---

Jakavi (ruxolitinib) licensed to Novartis ex-US, Tabrecta (capmatinib) licensed to Novartis worldwide, Olumiant (baricitinib) licensed to Lilly worldwide; these brands are trademarks of Novartis (Jakavi and Tabrecta) and Lilly (Olumiant). Iclusig (ponatinib) is a registered trademark of ARIAD. Monjuvi (tafasitamab-cxix) is a registered trademark of MorphoSys.

1. PMDA decision for pemigatinib in FGFR2 fusion positive locally advanced or metastatic biliary tract cancer.